Skip to search formSkip to main contentSkip to account menu

Refractory B-Cell Non-Hodgkin Lymphoma

Known as: B-Cell Lymphoma Refractory, Refractory B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin's Lymphoma 
B-cell non-Hodgkin lymphoma that is resistant to treatment.
National Institutes of Health

Related topics

Related topics

12 relations
Atypical lymphocyteB-LymphocytesHematopoietic and Lymphoid CellHematopoietic and Lymphoid Tissue

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
[Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells].
Objective: To investigate the factors influencing the efficacy of CD19 chimeric antigen receptor T (CAR-T) cells in the treatment… 
2018
2018
Ibrutinib in association with R-DHAP/ox for patients with relapsed/refractory b-cell lymphoma: Results of the escalating phase of the BIBLOS phase Ib LYSA study.
e19550Background: Ibrutinib (Ibru) has shown therapeutic activity in patients (pts) with various B-cells malignancies, making it… 
Review
2014
Review
2014
Clinical Translational Research of Chimeric Antigen Receptor-T (CAR-T) Cells for the Treatment of Relapsed and Refractory B-cell Lymphoma/Leukemia——Review
2013
2013
Rituximab used in three cases with relapsed non-Hodgkin's lymphoma.
Relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) patients have a poor prognosis. New treatment modalities have been… 
2013
2013
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell…
Patients with B cell malignancies refractory to allogeneic stem cell transplantation (SCT) can be treated by subsequent… 
2013
2013
Myeloablative Anti-CD20 Radioimmunotherapy +/- High-Dose Chemotherapy Followed by Autologous Stem Cell Support for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival
Background Radioimmunotherapy (RIT) has been used to treat relapsed/refractory CD20+ Non-Hodgkin lymphoma (NHL). Myeloablative… 
2011
2011
Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy
The treatment outcomes for B-cell non-Hodgkin lymphoma have improved since targeted agents such as rituximab were incorporated… 
2006
2006
[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
BACKGROUND & OBJECTIVE The prognosis of relapsed or refractory B-cell lymphoma is poor, with a short-term survival after… 
Review
2003
Review
2003
90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
OBJECTIVE Non-Hodgkin's lymphoma (NHL) is the most frequently diagnosed malignancy of the immune system, with more than 53,900… 
2000
2000
Salvage Therapy for Relapsed Mediastinal B-Cell Lymphoma with Allogeneic HLA-Identical Related Donor Bone Marrow Transplantation, Donor Lymphocyte Infusion and IDEC-C2B8
Primary B-cell lymphoma of the mediastinum is an aggressive non-Hodgkin's lymphoma with distinct clinicopathologic features… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)